FDA Decision to Stop Quick Review of Lab Developed Tests Raises Payment Concerns for Labs – Modern Healthcare

Read article - Cites research by Gregory Tsongalis, professor of pathology and laboratory medicine, whose lab is working to develop a molecular laboratory developed test (SARAS-CoV-2 LDT) for COVID-19. Tsongalis expressed concern that the FDA's emergency use authorization standards have been too lax.